Cancer and comparative imaging

ILAR Journal

Volumn 55, Issue 1, 2014, Pages 164-168

  LeBlanc, Amy K ^a,b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Comparative oncology; Molecular imaging

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; DISEASE MODEL; DOG; DOG DISEASES; DRUG DEVELOPMENT; HUMAN; MOLECULAR IMAGING; NEOPLASMS; PROCEDURES; TRENDS; VETERINARY;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; DRUG DISCOVERY; HUMANS; MOLECULAR IMAGING; NEOPLASMS;

EID: 84902486772     PISSN: 10842020     EISSN: 19306180     Source Type: Journal    
DOI: 10.1093/ilar/ilu014     Document Type: Article

References (42)

1. Altai M, Orlova A, Tolmachev V. 2013. Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine. Curr Pharm Des. Epub 11 Sept 2013.
2. Berry CR, Garg P. 2014. Perspectives in molecular imaging through translational research, human medicine, and veterinary medicine. Semin Nucl Med 44:66-75.
3. 18F-FDG and secondary short-lived tracers. IEEE Trans Nucl Sci 56:2750-2758.
4. 62Cu-ATSM PET in dogs with spontaneouslyoccurring tumors. Phys Med Biol 53:217-232.
5. 61Cu-ATSM PET in canine sinonasal tumors. J Nucl Med 54:1931-1937.
6. Bruehlmeier M, Kaser-Hotz B, Achermann R, Bley CR, Wergin M, Schubiger PA, Ametamey SM. 2005. Measurement of tumor hypoxia in spontaneous canine sarcomas. Vet Rad Ultrasound 46:348-354.
7. Cekanova M, Uddin MJ, Bartges JW, Callens A, Legendre AM, Rathore K, Wright L, Carter A, Marnett LJ. 2013. Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo. Cancer Prev Res (Phila). 6:466-476.
8. Clausen MM, Hansen AE, Rosenschold PM, Kjaer A, Kristensen AT, McEvoy FJ, Engelholm SA. 2013. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiat Oncol 8:262-270.
9. De Saint-Hubert M, Bauwens M, Verbruggen A, Mottaghy FM. 2012. Apoptosis imaging to monitor cancer therapy: The road to fast treatment evaluation? Curr Pharm Biotechnol 13:571-583.
10. Gordon I, Paoloni M, Mazcko C, Khanna C. 2009. The Comparative Oncology Trials Consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 6:e1000161.
11. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
12. 64Cu-ATSM autoradiography in spontaneous canine tumors: Comparison with pimonidazole hypoxia immunohistochemistry. Radiat Oncol 7:89.
13. 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol 102:424-428.
14. Hansen AE, McEvoy F, Svend A, Engelholm IL, Kristensen AT. 2011. FDG PET/CT imaging in canine cancer patients. Vet Rad Ultrasound 52:201-206.
15. Ibsen S, Schutt CE, Esener S. 2013. Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment. Drug Des Devel Ther 7:375-388.
16. James M, Ghambir SS. 2012. A molecular imaging primer: Modalities, imaging agents, and applications. Physiol Rev 92:897-965.
17. 18F]tetrafluoroborate: A PET imaging agent for thyroid disease and reported gene imaging of the sodium/iodide symporter. Eur J Nucl Mol Imaging 37:2108-2116.
18. Kopetz S, Lemos R, Powis G. 2012. The promise of patient-derived xenografts: The best laid plans of mice and men. Clin Cancer Res 18:5160-5162.
19. Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM. 2009. Use of 3-deoxy-3-[18F] fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma. Vet Radiol Ultrasound 50:660-668.
20. Lawrence JA, Forrest LJ, Turek MM, Miller PE, Mackie TR, Jaradat HA, Vail DM, Dubielzig RR, Chappell R, Mehta MP. 2010. Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensitymodulated radiation therapy. Vet Radiol Ultrasound 51:561-570.
21. LeBlanc AK, Jakoby BW, Townsend DW, Daniel GB. 2009. PET imaging in canine lymphoma and cutaneous mast cell tumor. Vet Rad Ultrasound 50:215-223.
22. 18FDG-PET/ CT to assess response to toceranib phosphate therapy in canine cancer. Vet Rad Ultrasound 53:348-357.
23. LeBlanc AK, Peremans K. 2014. PET and SPECT imaging in veterinary medicine. Semin Nucl Med 44:47-56.
24. Liu Z, Wang F. 2013. Development of RGD-based radiotracers for tumor imaging and therapy: Translating from bench to bedside. Curr Mol Med 13:1487-1505.
25. Madajewski B, Judy BF, Mouchli A, Kapoor V, Holt D, Wang MD, Nie S, Singhai S. 2012. Intraoperative near-infrared imaging of surgical wounds after tumor resections can detect residual disease. Clin Cancer Res 18:5741-5751.
26. 18F]-FLT as a biomarker of proliferation in oncology. PloS One 8:e58938.
27. Michalski MH, Chen X. 2011. Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging 38:358-377.
28. Naik S, Nace R, Barber G, Russell SJ. 2012. Potent systemic therapy of mulitple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther 19:443-450.
29. Paoloni M, Khanna C. 2008. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8:147-156.
30. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, LeBlanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti S. 2009. Lauching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 4: e4972.
31. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. 2006. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha(4)beta(1) integrin for in vivo tumor imaging. Nat Chem Biol 2:381-389.
32. Penheiter AR, Russell SJ, Carlson SK. 2012. The sodium-iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther 12:33-47.
33. Polom K, Murawa D, Rho YS, Nowaczyk P, Hunerbein M, Murawa P. 2011. Current trends and emerging future of indocyanine green usage in surgery and oncology: A literature review. Cancer 117:4812-4822.
34. Reske SN, Deisenhofer S. 2006. Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumor response than (18)F-fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 33(Suppl 1):38-43.
35. Rowell JL, McCarthy DO, Alvarez CE. 2011. Dog models of naturally occurring cancer. Trends Mol Med 17:380-388.
36. Seiler GS, Brown JC, Reetz JA, Taeymans O, Bucknoff M, Rossi F, Ohlerth O, Alder D, Rademacher N, Drost WT, Pollard RE, Travetti O, Pey P, Saunders JH, Shanaman MM, Oliveira CR, O'Brien RT, Gaschen L. 2013. Safety of contrast-enhanced ultrasonography in dogs and cats: 488 cases (2002-2011) J Am Vet Med Assoc 242:1255-1259.
37. Sohn H-J, Yang Y-J, Ryu J-S, Oh SJ, Im KC, Moon DH. 2008. [18F]fluorothymidine positron emission tomography before and 7 days after gefitinib therapy predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14:7423-7429.
38. Statham-Ringen KA, Selting KA, Lattimer JC, Henry CJ, Green JA, Bryan JN, Jia F, Lewis MR. 2012. Evaluation of a B-cell leukemialymphoma 2-specific radiolabeled peptide nucleic acid-peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma. Am J Vet Res 73:681-688.
39. Sulaimon SS, Kitchell BE. 2003. The basic biology of malignant melanoma: Molecular mechanisms of disease progression and comparative aspects. J Vet Intern Med 17:760-772.
40. Vaudaux C, Schneider U, Kaiser-Hotz B. 2007. Potential for intensity-modulated radiation therapy to permit dose escalation for canine nasal cancer. Vet Radiol Ultrasound 48:475-481.
41. Wilson KE, Wang TY, Willmann JK. 2013. Acoustic and photoacoustic molecular imaging of cancer. J Nucl Med 54:1851-1854.
42. Zwingenberger AL, Kent MS, Shi C, Taylor SL, Chen X, Lam KS. 2012. Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma. Vet Immunol Immunopathol 145:298-304.